Cargando…

Symptom versus exacerbation control: an evolution in GINA guidelines?

The article traces the concept of asthma control within GINA guidelines over the past 25 years. In the first 15 years after 1995, the main objective of asthma management was to obtain the control of all clinical and functional characteristics of asthma. A landmark study (GOAL) showed for the first t...

Descripción completa

Detalles Bibliográficos
Autores principales: Latorre, Manuela, Pistelli, Riccardo, Carpagnano, Giovanna Elisiana, Celi, Alessandro, Puxeddu, Ilaria, Scichilone, Nicola, Spanevello, Antonio, Canonica, Giorgio Walter, Paggiaro, Pierluigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469243/
https://www.ncbi.nlm.nih.gov/pubmed/37646243
http://dx.doi.org/10.1177/17534666231159261
_version_ 1785099399897022464
author Latorre, Manuela
Pistelli, Riccardo
Carpagnano, Giovanna Elisiana
Celi, Alessandro
Puxeddu, Ilaria
Scichilone, Nicola
Spanevello, Antonio
Canonica, Giorgio Walter
Paggiaro, Pierluigi
author_facet Latorre, Manuela
Pistelli, Riccardo
Carpagnano, Giovanna Elisiana
Celi, Alessandro
Puxeddu, Ilaria
Scichilone, Nicola
Spanevello, Antonio
Canonica, Giorgio Walter
Paggiaro, Pierluigi
author_sort Latorre, Manuela
collection PubMed
description The article traces the concept of asthma control within GINA guidelines over the past 25 years. In the first 15 years after 1995, the main objective of asthma management was to obtain the control of all clinical and functional characteristics of asthma. A landmark study (GOAL) showed for the first time that a good control of asthma is a reasonable outcome that can be achieved in a large proportion of asthmatics with a regular appropriate treatment. In the following years, more emphasis was placed on the role of exacerbations as critical manifestations of poor asthma control, whose frequency is associated with excessive FEV1 decline and increased risk of death. Accordingly, the 2014 GINA report makes a clear distinction between the control of the day-by-day symptoms and the reduction in the risk of severe exacerbations, stating that both conditions should be obtained. The 2019 update included a significant change in the management of mild asthma, prioritizing the prevention of exacerbations to that of mild symptoms. This view was repeated in the 2021 update, where the prevention of exacerbations, together with an acceptable symptom control with a minimal use of rescue medication, appeared to be the real main goal of asthma management. While a discrepancy between current symptoms and exacerbations may be present in mild asthma, a significant relationship between these two features is observed in moderate-severe asthma: a persistent poor symptom control is a major risk factor for exacerbations, whereas achieving symptom control through regular treatment is associated with a reduction in exacerbation rate. Thus, the opinion that frequent symptoms are not important in the absence of acute exacerbations should be discouraged, whereas education of patients to a good symptom perception and to improve adherence to regular treatment should be implemented. Furthermore, the persistence of risk factors, such as increased airway inflammation, even in a patient with minor daily symptoms, should be considered for optimizing treatment.
format Online
Article
Text
id pubmed-10469243
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-104692432023-09-01 Symptom versus exacerbation control: an evolution in GINA guidelines? Latorre, Manuela Pistelli, Riccardo Carpagnano, Giovanna Elisiana Celi, Alessandro Puxeddu, Ilaria Scichilone, Nicola Spanevello, Antonio Canonica, Giorgio Walter Paggiaro, Pierluigi Ther Adv Respir Dis Review The article traces the concept of asthma control within GINA guidelines over the past 25 years. In the first 15 years after 1995, the main objective of asthma management was to obtain the control of all clinical and functional characteristics of asthma. A landmark study (GOAL) showed for the first time that a good control of asthma is a reasonable outcome that can be achieved in a large proportion of asthmatics with a regular appropriate treatment. In the following years, more emphasis was placed on the role of exacerbations as critical manifestations of poor asthma control, whose frequency is associated with excessive FEV1 decline and increased risk of death. Accordingly, the 2014 GINA report makes a clear distinction between the control of the day-by-day symptoms and the reduction in the risk of severe exacerbations, stating that both conditions should be obtained. The 2019 update included a significant change in the management of mild asthma, prioritizing the prevention of exacerbations to that of mild symptoms. This view was repeated in the 2021 update, where the prevention of exacerbations, together with an acceptable symptom control with a minimal use of rescue medication, appeared to be the real main goal of asthma management. While a discrepancy between current symptoms and exacerbations may be present in mild asthma, a significant relationship between these two features is observed in moderate-severe asthma: a persistent poor symptom control is a major risk factor for exacerbations, whereas achieving symptom control through regular treatment is associated with a reduction in exacerbation rate. Thus, the opinion that frequent symptoms are not important in the absence of acute exacerbations should be discouraged, whereas education of patients to a good symptom perception and to improve adherence to regular treatment should be implemented. Furthermore, the persistence of risk factors, such as increased airway inflammation, even in a patient with minor daily symptoms, should be considered for optimizing treatment. SAGE Publications 2023-08-30 /pmc/articles/PMC10469243/ /pubmed/37646243 http://dx.doi.org/10.1177/17534666231159261 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Latorre, Manuela
Pistelli, Riccardo
Carpagnano, Giovanna Elisiana
Celi, Alessandro
Puxeddu, Ilaria
Scichilone, Nicola
Spanevello, Antonio
Canonica, Giorgio Walter
Paggiaro, Pierluigi
Symptom versus exacerbation control: an evolution in GINA guidelines?
title Symptom versus exacerbation control: an evolution in GINA guidelines?
title_full Symptom versus exacerbation control: an evolution in GINA guidelines?
title_fullStr Symptom versus exacerbation control: an evolution in GINA guidelines?
title_full_unstemmed Symptom versus exacerbation control: an evolution in GINA guidelines?
title_short Symptom versus exacerbation control: an evolution in GINA guidelines?
title_sort symptom versus exacerbation control: an evolution in gina guidelines?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469243/
https://www.ncbi.nlm.nih.gov/pubmed/37646243
http://dx.doi.org/10.1177/17534666231159261
work_keys_str_mv AT latorremanuela symptomversusexacerbationcontrolanevolutioninginaguidelines
AT pistelliriccardo symptomversusexacerbationcontrolanevolutioninginaguidelines
AT carpagnanogiovannaelisiana symptomversusexacerbationcontrolanevolutioninginaguidelines
AT celialessandro symptomversusexacerbationcontrolanevolutioninginaguidelines
AT puxedduilaria symptomversusexacerbationcontrolanevolutioninginaguidelines
AT scichilonenicola symptomversusexacerbationcontrolanevolutioninginaguidelines
AT spanevelloantonio symptomversusexacerbationcontrolanevolutioninginaguidelines
AT canonicagiorgiowalter symptomversusexacerbationcontrolanevolutioninginaguidelines
AT paggiaropierluigi symptomversusexacerbationcontrolanevolutioninginaguidelines